1. Academic Validation
  2. Novel tricyclic inhibitors of IkappaB kinase

Novel tricyclic inhibitors of IkappaB kinase

  • J Med Chem. 2009 Apr 9;52(7):1994-2005. doi: 10.1021/jm8015816.
James Kempson 1 Steven H Spergel Junqing Guo Claude Quesnelle Patrice Gill Dominique Belanger Alaric J Dyckman Tianle Li Scott H Watterson Charles M Langevine Jagabandhu Das Robert V Moquin Joseph A Furch Anne Marinier Marco Dodier Alain Martel David Nirschl Katy Van Kirk James R Burke Mark A Pattoli Kathleen Gillooly Kim W McIntyre Laishun Chen Zheng Yang Punit H Marathe David Wang-Iverson John H Dodd Murray McKinnon Joel C Barrish William J Pitts
Affiliations

Affiliation

  • 1 Departments of Discovery Chemistry, Discovery Biology, and Metabolism and Pharmacokinetics and Synthesis and Analysis Technology Team, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, USA.
Abstract

The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of IkappaB kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

Figures
Products